Kazuki Shirane

Kazuki Shirane

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
TSToko Shinkai
Toko Shinkai
KMKouji Masumoto
Kouji Masumoto
FCFumiko Chiba
Fumiko Chiba
KSKazuki Shirane
Kazuki Shirane
YTYasunari Tanaka
Yasunari Tanaka
SSShingo Sakashita
Shingo Sakashita

27 June 2025 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
HUHidehito Usui
Hidehito Usui
MSMasato Shinkai
Masato Shinkai
STSatoshi Tanaka
Satoshi Tanaka
RMRento Morishima
Rento Morishima
KSKazuki Shirane
Kazuki Shirane
NKNorihiko Kitagawa
Norihiko Kitagawa
Purpose: Superficial lymphatic malformation (SLM), previously known as lymphangioma circumscriptum, is characterized by skin lesions that sometimes require interventional treatment. However, an effective treatment has yet to be established. We proposed an effective sclerotherapy procedure based on the pathophysiology of SLM.Methods: Seven patients with SLM who were treated at our hospital between April 2015 and April 2024 were retrospectively enrolled. To maximize the treatment effects, sclerotherapy with bleomycin targeting the SLM and LM deep beneath the SLM was performed.Results: Of the seven patients, four were females, and three were males. The SLM sites were mucosal lesions in four cases and skin lesions in three cases. The median age at the first sclerotherapy was 10 (1–18) years. A median of one course (1–3) of sclerotherapy resulted in a marked reduction of SLM lesions on gross evaluation to the satisfaction of the patient. The median observation period was 451 (59–2,901) days. No serious complications occurred, except for transient vomiting in one patient and temporary skin pigmentation in two patients. No patient experienced recurrence requiring retreatment.Conclusion: Our study suggests that sclerotherapy for the SLM and LM deep beneath the SLM may be an effective treatment for SLM.

8 December 2023 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
KSKazuki Shirane
Kazuki Shirane
AYAi Yoshimi
Ai Yoshimi
TMTakayuki Masuko
Takayuki Masuko
DKDaigo Kajikawa
Daigo Kajikawa
MTMiki Toma
Miki Toma
TYToshihiro Yanai
Toshihiro Yanai
Children with trisomy 18 tend to develop hepatoblastoma. Since the introduction of appropriate management for organ malfunction, individuals with trisomy 18 have come to have a longer life expectancy. However, the predisposition to hepatoblastoma becomes a significant issue for the quality of a case. Here, we present a rare multifocal hepatoblastoma involving predominantly Couinaud segments 5 and 7 in a 10-month-old boy with trisomy 18. Though the first-line cisplatin monotherapy resulted in unsatisfactory tumor shrinkage, the second-line neoadjuvant chemotherapy administrating irinotecan and vincristine gave rise to significant tumor reduction in volume, leading to the completion of partial resection of the liver without the microscopic residual disease. The patient has been free from recurrence for 44 months. Because anatomical right hepatectomy can cause circulatory instability, including acute onset of pulmonary hypertension in trisomy 18 patients, physicians should balance treatment benefits and potential adverse effects. Our successful experience utilizing a combination of efficacious and less cardiotoxic neoadjuvant chemotherapy followed by the partial hepatectomy encourages physicians to treat a patient with trisomy 18 and tackle hepatoblastoma with a genetic background.

4 July 2024 in Surgery Today
Verified
Journal Article
Closed access
PDF file
YSYohei Sanmoto
Yohei Sanmoto
YGYudai Goto
Yudai Goto
KSKazuki Shirane
Kazuki Shirane
AKAkio Kawami
Akio Kawami
KMKouji Masumoto
Kouji Masumoto

26 May 2024 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
YGYudai Goto
Yudai Goto
KMKouji Masumoto
Kouji Masumoto
TJTakahiro Jimbo
Takahiro Jimbo
TSTakato Sasaki
Takato Sasaki
YTYasunari Tanaka
Yasunari Tanaka
KSKazuki Shirane
Kazuki Shirane

24 July 2025 in Children
Verified
Journal Article
Open access
PDF file
YGYudai Goto
Yudai Goto
KMKouji Masumoto
Kouji Masumoto
TSTakato Sasaki
Takato Sasaki
KSKazuki Shirane
Kazuki Shirane
TATomohiro Aoyama
Tomohiro Aoyama
TJTakahiro Jimbo
Takahiro Jimbo
Background/Objectives: Short bowel syndrome (SBS) is the leading cause of pediatric intestinal failure. Plasma citrulline is considered a marker indicating an enterocyte volume and may help evaluate the response to teduglutide; however, this interpretation may vary depending on the remnant bowel anatomy. Methods: We conducted a retrospective case series of four pediatric patients with SBS (aged < 15 years) who received teduglutide for 12 months at our hospital between 2018 and 2023. Changes in plasma citrulline levels and parenteral nutrition requirements were assessed in addition to bowel anatomy classification. Results: This study included two males and two females. All patients showed an increase in plasma citrulline levels and a reduction in the requirement for parenteral nutrition (PN) after 12 months of teduglutide treatment. In SBS type 2 (jejunocolic anastomosis), citrulline levels increased by 114% and 52%, with PN reduction rates of 100% and 30%, respectively. In SBS type 3 (jejunoileal anastomosis), citrulline levels increased by 13.6% and 34%, with PN reductions of 33% and 73%, respectively. Conclusions: Teduglutide treatment increased plasma citrulline levels and reduced PN levels in all cases. However, the magnitude of the citrulline change varied across bowel anatomy types, suggesting that the anatomical difference in the remnant bowel may influence the biomarker response. Further detailed pediatric cases are required to clarify the role of citrulline in evaluating GLP-2 analogue treatment outcomes.